To provide discovery services to support MSD’s global R&D
Hyderabad-headquartered Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), announced the expansion of its collaboration with MSD (tradename of Merck & Co., Rahway, NJ, USA) to provide discovery services and solutions supporting MSD’s global R&D efforts.
“We look forward to continuing to work with MSD researchers to advance its pipeline of therapeutic candidates,” said Manni Kantipudi, CEO, Aragen. “At Aragen, our team believes that ‘in every molecule is the possibility for better health’. By treating every project with urgency and focus, we look to discover and develop medicines for our collaborators that make a positive impact on patients.”
Dr Sudhir Kumar Singh, COO, Aragen, added, “On behalf of all Aragenites, I want to thank MSD for their trust and confidence in us and their decision to expand on the collaboration. Over the past several years, we have worked diligently at building a world-class scientific team, equipping them with state-of-the-art infrastructure, and inculcating a culture of customer-centricity.”